Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Non-LTR Retrotransposons

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Tuning the size and defect chemistry of TiO<sub>2</sub><i>via</i> flash nanoprecipitation for enhanced photocatalytic antibacterial activity.

Nanoscale·2026

Same author

Hydrogen-Bond-Assisted Hydroxylation of <i>o</i>-Fluorobenzamides: A Transition-Metal-Free Approach to Salicylamides.

Molecules (Basel, Switzerland)·2026

Same author

Reversible Tuning of Magnetic Order and Intrinsic Superconductivity in Strained FeTe Films via Stoichiometry Control.

ACS nano·2026

Same author

Inhibition of Histone Lactylation by Dichloromethane Extract From Patrinia scabiosaefolia Fisch on Acute Myeloid Leukemia Cells.

Chemistry & biodiversity·2026

Same author

[Chinese medicine Gandouling attenuates brain injury in hepatolenticular degeneration mice by inhibiting ferroptosis via the SIRT1/FoxO3 signaling pathway].

Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences·2026

Same author

Targeting dormant cancer cells: ferroptosis as a precision therapeutic strategy.

Cellular & molecular biology letters·2026

Search research articles

Related Experiment Video

Updated: May 12, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Long Non-Coding TP73-AS1: A Potential Biomarker and Therapeutic Target in Cancer.

Kejing Li^1,2, Dapeng Zhao^2,3,4, Xuena Liu^2,3,4

¹School of Basic Medical Sciences, Lanzhou University, Lanzhou 730000, China.

International Journal of Molecular Sciences

|May 7, 2025

Summary

Tumor protein 73 antisense RNA 1 (TP73-AS1) is a long non-coding RNA implicated in cancer development and drug resistance. Its regulatory mechanisms and clinical potential as a biomarker and therapeutic target are reviewed.

Keywords:

TP73-AS1 biomarker cancer long non-coding RNA molecular mechanism

More Related Videos

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Related Experiment Videos

Last Updated: May 12, 2025

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Fluorescence-based Monitoring of PAD4 Activity via a Pro-fluorescence Substrate Analog

Published on: November 5, 2014

Area of Science:

* Molecular oncology
* Cancer genomics
* RNA biology

Background:

* Tumor protein 73 antisense RNA 1 (TP73-AS1) is a long non-coding RNA (lncRNA) with dysregulated expression in various cancers.
* Aberrant TP73-AS1 expression correlates with cancer occurrence, drug resistance, and patient prognosis.
* Understanding TP73-AS1's regulatory roles offers new avenues for cancer diagnosis and treatment.

Purpose of the Study:

* To review the molecular structure and dual regulatory functions of TP73-AS1 in cancer.
* To elucidate the molecular mechanisms through which TP73-AS1 influences cancer progression.
* To highlight the clinical significance and therapeutic potential of TP73-AS1 in oncology.

Main Methods:

* Literature review of existing studies on TP73-AS1 in cancer.
* Analysis of TP73-AS1's molecular interactions, including protein binding and signaling pathway regulation.
* Examination of TP73-AS1's role as a molecular sponge for microRNAs.
* Compilation of data on TP73-AS1's involvement in specific cancers like gastric, lung, and colorectal cancer.

Main Results:

* TP73-AS1 exhibits diverse molecular mechanisms in cancer, including protein binding, signaling pathway modulation, and acting as a molecular sponge.
* TP73-AS1 plays a significant role in the pathogenesis of common malignancies such as gastric cancer (GC), lung cancer, and colorectal cancer (CRC).
* Single nucleotide polymorphisms (SNPs) in TP73-AS1 are associated with increased risk for GC and CRC.

Conclusions:

* TP73-AS1 is a crucial player in cancer development and progression through multiple molecular pathways.
* TP73-AS1 demonstrates significant potential as a diagnostic biomarker and a therapeutic target for various cancers.
* Further research into TP73-AS1's functions could lead to novel clinical strategies for cancer management.